I added as well. @5.12, 5.08 and 4.98. I very much liked how Marucci did not answer the CC questions w/respect to partnership potentials (CDX-011) in a way that would look like he was hyping. Seen enough of that over the years. I do believe that CDX-011 partnership will evolve in the first half '10.
Did Thomson's $0.29 loss estimate factor in the Curagen acquistion cost or was that purely operating losses? If the latter, I am not sure why these results are "bad". They are not blockbuster but no reason to tank either. Or is it simply a case of selling the news? Appreciate your input.